Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
Maslah N, Rety S, Bonnamy M, Aguinaga L, Huynh T, Parietti V, Giraudier S, Fenaux P, Cassinat B. Maslah N, et al. Among authors: parietti v. Leukemia. 2024 Jul;38(7):1630-1633. doi: 10.1038/s41375-024-02281-z. Epub 2024 May 22. Leukemia. 2024. PMID: 38777834 Free PMC article. No abstract available.
CXCR4 signaling determines the fate of hematopoietic multipotent progenitors by stimulating mTOR activity and mitochondrial metabolism.
Rondeau V, Kalogeraki M, Roland L, Nader ZA, Gourhand V, Bonaud A, Lemos J, Khamyath M, Moulin C, Schell B, Delord M, Bidaut G, Lecourt S, Freitas C, Anginot A, Mazure N, McDermott DH, Parietti V, Setterblad N, Dulphy N, Bachelerie F, Aurrand-Lions M, Stockholm D, Lobry C, Murphy PM, Espéli M, Mancini SJC, Balabanian K. Rondeau V, et al. Among authors: parietti v. Sci Signal. 2024 Oct 29;17(860):eadl5100. doi: 10.1126/scisignal.adl5100. Epub 2024 Oct 29. Sci Signal. 2024. PMID: 39471249
Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL).
Berrou J, Dupont M, Djamai H, Adicéam E, Parietti V, Kaci A, Clappier E, Cayuela JM, Baruchel A, Paublant F, Prudent R, Ghysdael J, Gardin C, Dombret H, Braun T. Berrou J, et al. Among authors: parietti v. J Clin Med. 2022 Nov 15;11(22):6761. doi: 10.3390/jcm11226761. J Clin Med. 2022. PMID: 36431240 Free PMC article.
Ambivalent role of FasL in murine acute graft-versus-host-disease.
Bernard-Bloch R, Lebrault E, Li X, Sutra Del Galy A, Garcia A, Doliger C, Parietti V, Legembre P, Socié G, Karray S. Bernard-Bloch R, et al. Among authors: parietti v. J Leukoc Biol. 2023 Sep 1;114(3):205-211. doi: 10.1093/jleuko/qiad040. J Leukoc Biol. 2023. PMID: 37013690
Targeting prostate tumor low-molecular weight tyrosine phosphatase for oxidation-sensitizing therapy.
Stanford SM, Nguyen TP, Chang J, Zhao Z, Hackman GL, Santelli E, Sanders CM, Katiki M, Dondossola E, Brauer BL, Diaz MA, Zhan Y, Ramsey SH, Watson PA, Sankaran B, Paindelli C, Parietti V, Mikos AG, Lodi A, Bagrodia A, Elliott A, McKay RR, Murali R, Tiziani S, Kettenbach AN, Bottini N. Stanford SM, et al. Among authors: parietti v. Sci Adv. 2024 Feb 2;10(5):eadg7887. doi: 10.1126/sciadv.adg7887. Epub 2024 Jan 31. Sci Adv. 2024. PMID: 38295166 Free PMC article.
27 results